CD73 inhibitors are a promising class of pharmaceutical agents that have gained attention for their therapeutic potential. These inhibitors target the CD73 enzyme, which is an ectonucleotidase expressed on the cell surface. CD73 plays a crucial role in adenosine production by catalyzing the conversion of AMP to adenosine, affecting various receptors and molecules, including A2A adenosine receptors. The mechanism of action involves blocking CD73, leading to increased levels of extracellular AMP, which can disrupt adenosine signaling pathways. CD73 inhibitors are being investigated for their use in multiple disease contexts. In cancer immunotherapy, these inhibitors are explored to enhance anti-tumor immune responses, reducing immunosuppression caused by adenosine. Additionally, they hold potential in inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease, where adenosine's immunomodulatory effects are implicated. Furthermore, CD73 inhibitors are being studied for their potential in cardiovascular diseases, including ischemic injury and myocardial infarction. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for an estimated 17.9 million deaths annually. Thus, developing CD73 inhibitors could offer significant therapeutic advancements in combating these widespread diseases. Extensive research is being conducted globally to discover new and novel molecules to be used, like oleclumab which is used for the treatment of many indications. The development and launch of new products will thus increase the CD73 Inhibitors market's revenue in the forecasted years.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. 17 companies have various products in their pipelines, with 13 products in different stages of clinical trials – 2 in Phase 3, 7 in Phase 2, and 12 in Phase 1 of the clinical trials.
Drugs in the Pipeline of CD73 Inhibitors
- Oleclumab (MEDI9447)
- Quemliclustat (AB680)
- Drebuxelimab (AK119)
- Uliledlimab (TJD5)
- Mupadolimab (CPI-006)
- IBI325
- NZV930
- Dalutrafusp Alfa (AGEN1423)
- ATG-037
- BMS-986179
- HB0045
- HLX23
- INCA00186
- INT-1B3
- IPH5301
- JAB-BX102
- LY 3475070
- ORIC-533
- PM1015
- PT199
- S95024
Clinical Activity and Developments of CD73 Inhibitors
As of July 2023, various companies have approximately 13 products for various diseases. For these diseases, 38 trials are being conducted by players globally. For instance,
- AstraZeneca is conducting a Phase 3 clinical trial of durvalumab plus oleclumab and durvalumab plus monalizumab in patients with Locally Advanced (Stage iii), unresectable Non-small Cell lung Cancer (NSCLC) who have not progressed following definitive, Platinum-Based Concurrent Chemoradiation Therapy that is expected to complete by May 2030.
- Catherine Spina Columbia University is conducting a Phase 2 clinical trial to test SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for men with hormone-sensitive Oligometastatic Prostate Cancer that is expected to be completed by December 2028.
- Arcus Biosciences. Inc. is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of combination therapies in patients with Advanced Upper Gastrointestinal Tract Malignancies that is expected to be completed by November 2025.
|
Molecule name |
Number of Studies |
|
oleclumab (MEDI9447) |
25 |
|
quemliclustat (AB680) |
9 |
|
drebuxelimab (AK119) |
7 |
|
uliledlimab (TJD5) |
4 |
|
mupadolimab (CPI-006) |
3 |
Target Indication Analysis of CD73 Inhibitors
CD73 inhibitors have emerged as promising candidates for various therapeutic indications, with some areas showing particular promise. One of the most prominent applications lies in cancer immunotherapy. By blocking CD73, these inhibitors prevent the conversion of AMP to adenosine in the tumor microenvironment, hindering the immunosuppressive effects of adenosine and bolstering anti-tumor immune responses. Consequently, CD73 inhibitors are being explored as potential agents to enhance the efficacy of existing cancer therapies and to initiate targeted immunotherapies. Another vital domain where CD73 inhibitors show significant potential is in the treatment of inflammatory diseases. By disrupting adenosine signaling, these inhibitors may help combat inflammation associated with conditions like rheumatoid arthritis and inflammatory bowel disease. Moreover, they hold promise in reducing tissue damage and promoting tissue repair in cardiovascular diseases, such as ischemic injury and myocardial infarction. The versatility of CD73 inhibitors also extends to fibrotic diseases, where they may impede fibrosis development and halt disease progression. As ongoing research uncovers more about CD73's role in various pathologies, the applications of these inhibitors are likely to expand further, providing novel therapeutic opportunities for multiple debilitating conditions.
CD73 Inhibitors Regional Analysis
CD73 Inhibitors Market
According to the Globocon 2020 report, 1 in 5 people develop cancer during their lifetime globally and more than 50 million people are living within 5 years of a past cancer diagnosis. Breast and Lung cancer are the most prevalent cancer globally with 1 in every four cancer diagnosed being Breast cancer in women globally followed by Colorectal and Lung cancer in females respectively. The global prevalennce of Rheumatoid Arthritis is in the range of 0.5% to 1%. The prevalence varies with factors including sex, region and geography, age, lifestyle and socio-economic factors. Hence, there exists a great opportunity for CD73 Inhibitors in thee coming years.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Currently, no CD73 Inhibitor has been FDA-approved.
These are being evaluated for treating Autoimmune diseases like Rheumatoid Arthritis, various types of cancers, inflammatory diseases, and others.
AstraZeneca, Arcus Biosciences Inc, Gilead Sciences, Akeso Inc, and I-Mab are some of the major market players for CD73 Inhibitors.
The rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of cancers like Breast cancer, Ovarian cancer, and others are the critical opportunities for CD73 Inhibitors in the market.
- AstraZeneca
- Arcus Biosciences Inc
- Gilead Sciences
- Akeso Inc
- I-Mab
- Tracon Pharmaceuticals
- Corvus Pharmaceuticals
- Innovent Biologics
- Novartis
- Agenus Inc
- Antengene Corp
- BMS
- Zhejiang Huahai Pharma
- Fosun Pharmaceutical
- Incyte
- InteRNA Tech
- Innate Pharmaa S.A.
- Jacobio Pharmaceuticals Group Co. Ltd
- Eli Lilly
- ORIC Pharmaceuticals
- Biotheus
- Phanes Therapeutics
- Servier Pharmaceuticals